2024-03-29T08:33:13Zhttps://eprints.lib.hokudai.ac.jp/dspace-oai/requestoai:eprints.lib.hokudai.ac.jp:2115/821452022-11-17T02:08:08Zhdl_2115_20040hdl_2115_121Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case reportUmemura, Machiko1000020447460Suda, GokiTsukamoto, ShihoriEbata, KoTakahash, ShinjiroSasaki, TakashiNakajima, SaeHirata, KojiOzasa, MarikoTakano, MasatoshiKatagiri, MasakiSakamoto, Naoyametadata only accessGlecaprevirHepatitis C virusPibrentasvirDirect-acting antiviralhepatitis C flare490Background In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. However, appropriate therapeutic strategies for managing hepatitis C flare during R-CHOP have not been established, and this issue is complicated by conflicting results regarding the use of direct-acting antivirals in patients with uncontrolled malignancies. Case presentation We report the first case of effective and safe treatment with on-demand 8-week glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in a patient with diffuse large B-cell lymphoma (DLBCL). The patient completed five additional courses of R-CHOP without hepatic toxicity. A complete response of DLBCL and a sustained virological response were observed at 24 weeks after glecaprevir and pibrentasvir completion. Conclusion On-demand, direct-acting antivirals could be a novel strategy for managing hepatitis C flare during R-CHOP.BioMed Central2021-04-27engjournal articleNAhttp://hdl.handle.net/2115/82145https://doi.org/10.1186/s12879-021-06091-xBMC infectious diseases211389